Financiere de Tubize SA
XBRU:TUB
Financiere de Tubize SA
XBRU:TUB
Price:
206
EUR
-2.6%
Market Closed
Market Cap:
€9.2B
Relative Value
The Relative Value of one
TUB
stock under the Base Case scenario is
0.68
EUR.
Compared to the current market price of 206 EUR,
Financiere de Tubize SA
is
Overvalued by 100%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TUB
Relative Value
Base Case
0.68
EUR
Overvaluation 100%
Multiples Across Competitors
TUB Competitors Multiples
Financiere de Tubize SA Competitors
Financiere de Tubize SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| BE |
|
Financiere de Tubize SA
XBRU:TUB
|
9.2B EUR | 0 | 98.9 | -3 499.4 | -3 499.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 4.9 | 28.3 | 15.7 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
